Education and Training
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: filgrastim
- drug: vincristine sulfate
- radiation: radiation therapy
- drug: cisplatin
- drug: cyclophosphamide
- drug: cytarabine
- drug: dexrazoxane hydrochloride
- drug: doxorubicin hydrochloride
- drug: etoposide
- drug: leucovorin calcium
- drug: methotrexate
- drug: temozolomide
- drug: therapeutic hydrocortisone
- drug: Dactinomycin
Eligibility
DISEASE CHARACTERISTICS:
- Histologically confirmed primary intracranial Central Nervous System (CNS) atypical
teratoid/rhabdoid tumor OR
- Tumor tissue that possesses the INI-1 gene mutation
- No metastases that disseminate outside the CNS by abdominal and chest computer
tomography (CT) scans, kidney imaging, and bone marrow biopsy
- No obstruction of cerebrospinal fluid (CSF) flow by CSF flow study
- Definitive surgical resection of tumor within the past 35 days
PATIENT CHARACTERISTICS:
Age
- 18 and under
Performance status
- Karnofsky 50-100% OR
- Lansky 50-100%
Life expectancy
- Not specified
Hematopoietic
- Hemoglobin > 10 g/dL
- Absolute neutrophil count > 1,000/mm^3
- Platelet count > 100,000/mm^3
Hepatic
- Bilirubin ≤ 1.5 mg/dL
- SGPT < 10 times normal
Renal
- Creatinine ≤ 1.5 times normal
Other
- Willing to have placement of central venous access line
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy
Endocrine therapy
- Prior steroids allowed
Radiotherapy
- No prior radiotherapy
Surgery
- See Disease Characteristics
Other
- No other prior or concurrent investigational agents
- Concurrent anticonvulsant agents allowed
Ages Eligible for Study
N/A - 18 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Paul Fisher
6507258630
Not Recruiting